The Medical Letter on Drugs and Therapeutics
Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Asenapine (Saphris – Schering-Plough), a dibenzo-oxepino pyrrole, has been approved by the FDA in a sublingual tablet formulation for acute treatment of schizophrenia and manic or mixed episodes associated with bipolar disorder. It is the sixth second-generation antipsychotic approved by the FDA for use in bipolar disorder.1

MECHANISM OF ACTION — Asenapine, like most second-generation antipsychotics, is an antagonist at dopamine D2 and serotonin 5-HT2A receptors. It also has high affinity for other dopamine and serotonin receptors, as well as alpha-adrenergic and histaminergic (H1) receptors.2 Asenapine has low affinity for muscarinic receptors.

PHARMACOKINETICS — When swallowed, the bioavailability of asenapine is poor (< 2%) because of extensive first-pass metabolism. Placed under the tongue, the drug ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Asenapine (Saphris) Sublingual Tablets for Schizophrenia and Bipolar Disorder
Article code: 1331a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian